CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Jan A. Burger, Fredrick B. Hagemeister et al.|British Journal of Haematology|2015Cited by 76
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Farhad Ravandi, Tapan M. Kadia et al.|Blood Advances|2023Cited by 29